|
gptkbp:instanceOf
|
vaccine
|
|
gptkbp:administeredBy
|
intramuscular injection
|
|
gptkbp:adverseEvents
|
rare, similar to other COVID-19 vaccines
|
|
gptkbp:alsoKnownAs
|
gptkb:Gam-COVID-Vac
|
|
gptkbp:approvedBy
|
gptkb:Russia
August 2020
|
|
gptkbp:associatedWith
|
gptkb:Sputnik_Light
|
|
gptkbp:boosters
|
yes
|
|
gptkbp:clinicalTrialPhase
|
Phase III completed
|
|
gptkbp:countryOfOrigin
|
gptkb:Russia
|
|
gptkbp:developedBy
|
gptkb:Gamaleya_Research_Institute
|
|
gptkbp:distribution
|
exported to over 70 countries
|
|
gptkbp:distributionChallenges
|
regulatory and supply chain issues
|
|
gptkbp:dosesRequired
|
2
|
|
gptkbp:effect
|
91.6% (reported in interim analysis)
|
|
gptkbp:emergencyServices
|
granted in several countries
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sputnik V
|
|
gptkbp:manufacturer
|
gptkb:Brazil
gptkb:India
gptkb:Russia
gptkb:South_Korea
|
|
gptkbp:namedAfter
|
gptkb:Sputnik_1_satellite
|
|
gptkbp:pricePerDose
|
less than $10 (reported)
|
|
gptkbp:publishedIn
|
gptkb:The_Lancet_(2021)
|
|
gptkbp:regulates
|
gptkb:Russian_Ministry_of_Health
|
|
gptkbp:sideEffect
|
mild, similar to other vaccines
|
|
gptkbp:storage
|
2–8°C
|
|
gptkbp:target
|
gptkb:COVID-19
|
|
gptkbp:technology
|
heterologous prime-boost
|
|
gptkbp:type
|
viral vector vaccine
|
|
gptkbp:vectorUsed
|
adenovirus Ad26 and Ad5
|
|
gptkbp:WHOStatus
|
not approved by WHO as of 2024
|
|
gptkbp:bfsParent
|
gptkb:COVID-19
gptkb:COVID-19_pandemic
|
|
gptkbp:bfsLayer
|
4
|